A new trading day began on Friday, with Apogee Therapeutics Inc (NASDAQ: APGE) stock price down -16.58% from the previous day of trading, before settling in for the closing price of $49.21. APGE’s price has ranged from $29.06 to $72.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 7.87%. With a float of $36.30 million, this company’s outstanding shares have now reached $45.02 million.
In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Apogee Therapeutics Inc (APGE) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Apogee Therapeutics Inc is 37.97%, while institutional ownership is 80.63%. The most recent insider transaction that took place on Jan 08 ’25, was worth 732,693. In this transaction Chief Executive Officer of this company sold 15,000 shares at a rate of $48.85, taking the stock ownership to the 1,309,487 shares. Before that another transaction happened on Jan 08 ’25, when Company’s Officer proposed sale 15,000 for $48.84, making the entire transaction worth $732,675.
Apogee Therapeutics Inc (APGE) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.87% per share during the next fiscal year.
Apogee Therapeutics Inc (NASDAQ: APGE) Trading Performance Indicators
Here are Apogee Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 16.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.73, a number that is poised to hit -1.08 in the next quarter and is forecasted to reach -4.32 in one year’s time.
Technical Analysis of Apogee Therapeutics Inc (APGE)
Apogee Therapeutics Inc (NASDAQ: APGE) saw its 5-day average volume 0.55 million, a positive change from its year-to-date volume of 0.51 million. As of the previous 9 days, the stock’s Stochastic %D was 60.08%. Additionally, its Average True Range was 3.37.
During the past 100 days, Apogee Therapeutics Inc’s (APGE) raw stochastic average was set at 8.10%, which indicates a significant decrease from 17.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.31% in the past 14 days, which was higher than the 66.34% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $49.04, while its 200-day Moving Average is $49.36. Nevertheless, the first resistance level for the watch stands at $46.57 in the near term. At $52.09, the stock is likely to face the second major resistance level. The third major resistance level sits at $55.84. If the price goes on to break the first support level at $37.30, it is likely to go to the next support level at $33.55. The third support level lies at $28.03 if the price breaches the second support level.
Apogee Therapeutics Inc (NASDAQ: APGE) Key Stats
With a market capitalization of 2.40 billion, the company has a total of 45,027K Shares Outstanding. Currently, annual sales are 0 K while annual income is -83,990 K. The company’s previous quarter sales were 0 K while its latest quarter income was -49,020 K.
